Τετάρτη 23 Δεκεμβρίου 2015

Adjuvant Denosumab Improves Disease-Free Survival in Estrogen Receptor–Positive Postmenopausal Breast Cancer

There is good news about denosumab (Prolia). The primary analysis of the ABCSG-18 trial showed that adjuvant denosumab (given at low doses) reduces the risk of clinical fracture by 50% in postmenopausal women with early breast cancer who are taking an aro

from Cancer via ola Kala on Inoreader http://ift.tt/1mBscsy
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου